Equity Overview
Price & Market Data
Price: $1.60
Daily Change: -$0.0401 / 2.51%
Range: $1.49 - $1.64
Market Cap: $30,593,336
Volume: 269,278
Performance Metrics
1 Week: 28.69%
1 Month: -15.14%
3 Months: -68.09%
6 Months: -83.70%
1 Year: -86.78%
YTD: -68.79%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.